(VIANEWS) – MEDISTIM (MEDI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MEDISTIM (MEDI.OL) | kr191.50 | 2.34% | 32.37% |
| ESSILORLUXOTTICA (EL.PA) | €175.34 | 1.92% | 6.44% |
| LUMIBIRD (LBIRD.PA) | €13.12 | 1.25% | 5.68% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MEDISTIM (MEDI.OL)
2.34% Forward Dividend Yield and 32.37% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.41.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 29.88. Meaning, the purchaser of the share is investing kr29.88 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 526.89M for the twelve trailing months.
More news about MEDISTIM.
2. ESSILORLUXOTTICA (EL.PA)
1.92% Forward Dividend Yield and 6.44% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.21.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 33.65. Meaning, the purchaser of the share is investing €33.65 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.44%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 22, 2023, the estimated forward annual dividend rate is 3.23 and the estimated forward annual dividend yield is 1.92%.
More news about ESSILORLUXOTTICA.
3. LUMIBIRD (LBIRD.PA)
1.25% Forward Dividend Yield and 5.68% Return On Equity
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two segments, Photonics and Medical. The company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, Laser rangefinder and LiDAR wind doppler LiDAR, medical and ophthalmological equipment. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The company was incorporated in 1970 and is headquartered in Lannion, France.
Earnings Per Share
As for profitability, LUMIBIRD has a trailing twelve months EPS of €0.45.
PE Ratio
LUMIBIRD has a trailing twelve months price to earnings ratio of 29.16. Meaning, the purchaser of the share is investing €29.16 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
Volatility
LUMIBIRD’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.93%, a negative 0.46%, and a positive 1.50%.
LUMIBIRD’s highest amplitude of average volatility was 1.75% (last week), 1.61% (last month), and 1.50% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LUMIBIRD’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for LUMIBIRD is 256 which is 94.3% below its average volume of 4492.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 206.53M for the twelve trailing months.
More news about LUMIBIRD.
